The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
The report is the latest indictment of America’s broken healthcare system.
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
The Federal Trade Commission has released its second report ... The report accuses CVS’ Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx of jacking up the price of lifesaving ...
the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N CVS Caremark and Cigna's CI.N Express Scripts ...
Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.
A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit managers investigated, three of them (CVS Caremark, Express Scripts and ...
The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results